Floatz logo

a2b694

Rectal Cancer

A2 Biotherapeutics Inc.Cell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

113 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Fudan University
Phase 2BBB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4BBB
Eloxatin
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB
FLUOROURACILUM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BBB

View all 50 →

Same molecule, other indications

a2b694 is also rated in:

non-small cell squamous lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
pancreatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
mesotheliomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →